Literature DB >> 15611141

Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad.14-3-3 signaling pathways.

Hang Yin1, Lee Chao, Julie Chao.   

Abstract

Our previous study has shown that human tissue kallikrein protected against ischemia/reperfusion-induced myocardial injury. In the present study, we investigated the protective role of local kallikrein gene delivery in ischemia/reperfusion-induced cardiomyocyte apoptosis and its signaling mechanisms in promoting cardiomyocyte survival. Adenovirus carrying the human tissue kallikrein gene was delivered locally into the heart using a catheter-based technique. Expression and localization of recombinant human kallikrein in rat myocardium after gene transfer were determined immunohistochemically. Kallikrein gene delivery markedly reduced reperfusion-induced cardiomyocyte apoptosis identified by both in situ nick end-labeling and DNA fragmentation. Delivery of the kallikrein gene increased phosphorylation of Src, Akt, glycogen synthase kinase (GSK)-3beta, and Bad(Ser-136) but reduced caspase-3 activation in rat myocardium after reperfusion. The protective effect of kallikrein on apoptosis and its signaling mediators was blocked by icatibant and dominant-negative Akt, indicating a kinin B2 receptor-Akt-mediated event. Similarly, kinin or transduction of kallikrein in cultured cardiomyocytes promoted cell viability and attenuated apoptosis induced by hypoxia/reoxygenation. The effect of kallikrein on cardiomyocyte survival was blocked by dominant-negative Akt and a constitutively active mutant of GSK-3beta, but it was facilitated by constitutively active Akt, catalytically inactive GSK-3beta, lithium, and caspase-3 inhibitor. Moreover, kallikrein promoted Bad.14-3-3 complex formation and inhibited Akt-GSK-3beta-dependent activation of caspase-3, whereas caspase-3 administration caused reduction of the Bad.14-3-3 complex, indicating an interaction between Akt-GSK-caspase-3 and Akt-Bad.14-3-3 signaling pathways. In conclusion, kallikrein/kinin protects against cardiomyocyte apoptosis in vivo and in vitro via Akt-Bad.14-3-3 and Akt-GSK-3beta-caspase-3 signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15611141     DOI: 10.1074/jbc.M407179200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

Review 1.  The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways.

Authors:  Eléonore Beurel; Richard S Jope
Journal:  Prog Neurobiol       Date:  2006-08-28       Impact factor: 11.685

2.  Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling.

Authors:  Hang Yin; Julie Chao; Michael Bader; Lee Chao
Journal:  Peptides       Date:  2007-05-25       Impact factor: 3.750

Review 3.  Role of glycogen synthase kinase-3beta in cardioprotection.

Authors:  Magdalena Juhaszova; Dmitry B Zorov; Yael Yaniv; H Bradley Nuss; Su Wang; Steven J Sollott
Journal:  Circ Res       Date:  2009-06-05       Impact factor: 17.367

4.  Inhibition of anti-apoptotic signals by Wortmannin induces apoptosis in the remote myocardium after LAD ligation: evidence for a protein kinase C-δ-dependent pathway.

Authors:  Stephan Wiedemann; Teresa Wessela; Kerstin Schwarz; Dirk Joachim; Marcel Jercke; Ruth H Strasser; Bernd Ebner; Gregor Simonis
Journal:  Mol Cell Biochem       Date:  2012-09-27       Impact factor: 3.396

Review 5.  Myocardial AKT: the omnipresent nexus.

Authors:  Mark A Sussman; Mirko Völkers; Kimberlee Fischer; Brandi Bailey; Christopher T Cottage; Shabana Din; Natalie Gude; Daniele Avitabile; Roberto Alvarez; Balaji Sundararaman; Pearl Quijada; Matt Mason; Mathias H Konstandin; Amy Malhowski; Zhaokang Cheng; Mohsin Khan; Michael McGregor
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

6.  Tongxinluo modulates cytokine secretion by cardiac microvascular endothelial cells in ischemia/reperfusion injury.

Authors:  Hehe Cui; Na Li; Xiangdong Li; Kang Qi; Qing Li; Chen Jin; Tianjie Wang; Lian Duan; Leipei Jiang; Guihao Chen; Zhigang Wang; Cong Wei; Yuejin Yang
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

Review 7.  Kallikrein-kinin in stem cell therapy.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

8.  Identification of the prosurvival activity of nerve growth factor on cardiac myocytes.

Authors:  A Caporali; G B Sala-Newby; M Meloni; G Graiani; E Pani; B Cristofaro; A C Newby; P Madeddu; C Emanueli
Journal:  Cell Death Differ       Date:  2007-11-09       Impact factor: 15.828

9.  Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction.

Authors:  Yu-Yu Yao; Hang Yin; Bo Shen; Lee Chao; Julie Chao
Journal:  J Card Fail       Date:  2007-09       Impact factor: 5.712

10.  Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation.

Authors:  Julie Chao; Hang Yin; Lin Gao; Makoto Hagiwara; Bo Shen; Zhi-Rong Yang; Lee Chao
Journal:  Hypertension       Date:  2008-09-02       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.